3 research outputs found
Results from the DELCODE study
Previous studies have demonstrated increased tau plasma levels in patients
with Alzheimer’s disease (AD) and mild cognitive impairment (MCI) due to AD.
Much less is known whether increased tau plasma levels can already be detected
in the pre-MCI stage of subjective cognitive decline (SCD). In the present
study we measured tau plasma levels in 111 SCD patients and 134 age- and
gender-matched cognitively healthy controls participating in the DZNE (German
Center for Neurodegenerative Diseases) longitudinal study on cognition and
dementia (DELCODE). Tau plasma levels were measured using ultra-sensitive,
single-molecule array (Simoa) technology. We found no significant different
tau plasma levels in SCD (3.4 pg/ml) compared with healthy controls (3.6
pg/ml) after controlling for age, gender, and education (p = 0.137). In
addition, tau plasma levels did not correlate with Aβ42 (r = 0.073; p =
0.634), tau (r = −0.179; p = 0.240), and p-tau181 (r = −0.208; p = 0.171)
cerebrospinal fluid (CSF) levels in a subgroup of 45 SCD patients with
available CSF. In conclusion, plasma tau is not increased in SCD patients. In
addition, the lack of correlation between tau in plasma and CSF in the
examined cohort suggests that tau levels are affected by different factors in
both biofluids
Results from the DELCODE study
Previous studies have demonstrated increased tau plasma levels in patients
with Alzheimer’s disease (AD) and mild cognitive impairment (MCI) due to AD.
Much less is known whether increased tau plasma levels can already be detected
in the pre-MCI stage of subjective cognitive decline (SCD). In the present
study we measured tau plasma levels in 111 SCD patients and 134 age- and
gender-matched cognitively healthy controls participating in the DZNE (German
Center for Neurodegenerative Diseases) longitudinal study on cognition and
dementia (DELCODE). Tau plasma levels were measured using ultra-sensitive,
single-molecule array (Simoa) technology. We found no significant different
tau plasma levels in SCD (3.4 pg/ml) compared with healthy controls (3.6
pg/ml) after controlling for age, gender, and education (p = 0.137). In
addition, tau plasma levels did not correlate with Aβ42 (r = 0.073; p =
0.634), tau (r = −0.179; p = 0.240), and p-tau181 (r = −0.208; p = 0.171)
cerebrospinal fluid (CSF) levels in a subgroup of 45 SCD patients with
available CSF. In conclusion, plasma tau is not increased in SCD patients. In
addition, the lack of correlation between tau in plasma and CSF in the
examined cohort suggests that tau levels are affected by different factors in
both biofluids